Scientists have demonstrated a method for generating several key types of eye tissue from human stem cells in a way that mirrors whole eye development.
When transplanted to an animal model of corneal blindness, these tissues are shown to repair the front of the eye and restore vision, which scientists say could pave the way for human clinical trials of anterior eye transplantation to restore lost or damaged vision.
A collaborative team comprising researchers from Cardiff University and Osaka University in Japan describe their findings today (embargo: 18:00GMT, 09 March, 2016) in Nature.
The eye is composed of highly specialized tissues that are derived from a variety of cell lineages during development.
Previous studies have demonstrated that particular cell types, such as those that constitute the retina or cornea, can be created in the laboratory from pluripotent stem cells. However, these studies do not represent the complexity of whole eye development.
This latest study reports the generation of multiple cell lineages of the eye, including the lens, cornea, and conjunctiva, using human induced pluripotent stem cells.
The scientists have been able to show that the corneal epithelial cells can be cultivated and transplanted onto the eyes of rabbits with experimentally induced blindness to surgically repair the front of the eye.
Study co-author, Professor Andrew Quantock, said: “This research shows that various types of human stem cells are able to take on the characteristics of the cornea, lens and retina.
“Importantly, it demonstrates that one cell type – the corneal epithelium – could be further grown in the lab and then transplanted on to a rabbit’s eye where it was functional, achieving recovered vision.
“Our work not only holds potential for developing cells for treatment of other areas of the eye, but could set the stage for future human clinical trials of anterior eye transplantation to restore visual function.”
The Latest on: Stem cell transplantation
via Google News
The Latest on: Stem cell transplantation
- Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Knowon March 5, 2021 at 11:50 am
Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team. What Happened: Jonathan Hoggatt, who was a principal ...
- Cole MacKay urges Canadians to join stem cell registryon March 5, 2021 at 7:43 am
Canada Life, a Canadian insurance, wealth management and benefits provider has teamed up with Canadian Blood Services to support their #BeAHero campaign, encouraging Canadians to 'be a hero’ and join ...
- Harvard stem cell research lead Jonathan Hoggatt joins Moderna as director of hematologyon March 5, 2021 at 1:21 am
Moderna has poached major stem cell researcher Jonathan Hoggatt, Ph.D., to lead its hematology R&D as it gears up for a future outside of COVID vaccines. Hoggatt comes from the Harvard Stem Cell ...
- High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantationon March 3, 2021 at 4:00 pm
It is now well-established that regulatory T cells (Treg) represent a heterogeneous group of CD4 + T cells. Previous studies have demonstrated that Treg homeostasis was impacted by allogeneic ...
- Awareness and stem-cell donors are key to treat Aplastic Anaemia Awarenesson March 3, 2021 at 3:16 pm
While the percentage of lives claimed due to the illness is high, there are several treatment options including stem-cell transfusions to mitigate this.
- Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide | Bone Marrow Transplantationon March 3, 2021 at 10:37 am
Higher infused total nucleated cell dose (TNC) in allogeneic bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy) is associated with improved overall survival. As many centers ...
- Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaon March 2, 2021 at 5:59 pm
After a first autologous stem cell transplant, newly diagnosed multiple myeloma is usually monitored until the first relapse, and not actively treated. Lenalidomide is the only treatment option ...
- Treating Parkinson’s Disease with Individualized Brain Cell Graftson March 2, 2021 at 5:00 am
Movement and depression symptoms associated with Parkinson's disease were relieved in monkeys's brain by grafted neurons.
- How You Can Join the Canadian Blood Services Stem Cell Registryon March 1, 2021 at 11:22 pm
Each year, hundreds of patients, in Canada with diseases, like Mackenzie, need a stem cell transplant to save their life. If you’re between the ages of 17 and 35, visit blood.ca/stemcells for more ...
- Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Boardon February 25, 2021 at 3:40 am
Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), a developer of Veto Cell-based innovative immunotherapy technologies that facilitate mismatched donor stem cell (e.g. bone marrow) and ...
via Bing News